Sheep anti Human Glypican-3 (GPC3)

Research Use Only
ApplicationsImmunoHistoChemistry, Western Blot
Product group Antibodies
€ 332,00
500 ug
Sign in to order and to see your custom pricing.
Large volume orders?
Order with a bulk request


  • Supplier
  • Product Name
    Sheep anti Human Glypican-3 (GPC3)
  • Delivery Days Customer
  • Applications
    ImmunoHistoChemistry, Western Blot
  • Applications Supplier
    Immunohistochemistry (paraffin);Western Blotting;Immunohistochemistry (paraffin)
  • Category Supplier
    Primary antibodies
  • Certification
    Research Use Only
  • Concentration
    See vial for concentration
  • Host
  • Isotype
  • Scientific Description
    GPC3, GPC-3, OCI5, OCI-5, GTR2-2, MXR7
  • Shelf life instruction
    See expiration date on vial
  • Reactivity
  • Reactivity Supplier
  • Reactivity Supplier Note
    C terminal recombinant protein (~70aa) which does not overlap with clone 1G12 epitope)
  • Storage Instruction
    Product should be stored at -20ºC. Aliquot to avoid freeze/thaw cycles


  • 1. Lai, J.P., et al. Sulfatase 2 up-regulates glypican 3, promotes fibroblast growth factor signaling, and decreases survival in hepatocellular carcinoma. Hepatology 2008, 47, 1211-1222. 2. Zynger, D.L., et al. Expression of glypican 3 in ovarian and extragonadal germ cell tumors. Am. J. Clin. Pathol. 2008, 130, 224-230. 3. Anatelli, F., et al. Value of glypican 3 immunostaining in the diagnosis of hepatocellular carcinoma on needle biopsy. Am. J. Clin. Pathol. 2008, 130, 219-223. 4. Yamanaka, K., et al. Immunohistochemical study of glypican 3 in thyroid cancer. Oncology 2007, 73, 389-394. 5. Filmus, J., et al. Glypicans. Genome Biol. 2008, 9, 224. 6. Baumhoer, D., et al. Glypican 3 expression in human nonneoplastic, preneoplastic, and neoplastic tissues: a tissue microarray analysis of 4,387 tissue samples. Am. J. Clin. Pathol. 2008, 129, 899-906. 7. Capurro, M.I., et al. Glypican-3 inhibits Hedgehog signaling during development by competing with patched for Hedgehog binding. Dev. Cell 2008, 14, 700-711. 8. Motomura, Y., et al. HLA-A2 and -A24-restricted glypican-3-derived peptide vaccine induces specific CTLs: preclinical study using mice. Int. J. Oncol. 2008, 32, 985-990. 9. Cheng, W., et al. Glypican-3-mediated oncogenesis involves the Insulin-like growth factor-signaling pathway. Carcinogenesis 2008, 29, 1319-1326.